Meis2 Upregulation Cuts Seizures to 0.15 a Day, Restoring Cognition in Adult NDD Mice
Updated
Updated · Drug Target Review · Aug 13
Meis2 Upregulation Cuts Seizures to 0.15 a Day, Restoring Cognition in Adult NDD Mice
3 articles · Updated · Drug Target Review · Aug 13
Summary
Adult Cntnap2 knockout mice given targeted Meis2 upregulation in hippocampal PV interneurons showed seizure frequency fall to 0.15 a day from 1.83, with only 3 of 12 mice seizing versus 10 of 14 controls.
The intervention restored experience-dependent PV interneuron plasticity in the CA3/CA2 circuit, rebuilding perisomatic synapses, boosting feedforward inhibition and normalizing the excitation-inhibition imbalance linked to hyperexcitability.
Behavioral and network measures improved alongside the circuit rescue: treated mice regained object-location and social-recognition performance, showed stronger social-ensemble reactivation, and recovered sharp-wave ripple rate, power and duration during NREM sleep.
An input-specific translatome screen identified many upregulated plasticity genes tied to autism, epilepsy, schizophrenia and bipolar disorder, suggesting impaired PV interneuron plasticity is a shared mechanism across neurodevelopmental disorders.
The study argues that restoring this plasticity in adulthood can reverse developmental circuit deficits, positioning Meis2 and related genes as potential therapeutic targets rather than early-life-only interventions.
Could reactivating a single gene in adulthood reverse lifelong autism and epilepsy symptoms without needing early developmental intervention?
If adult brains remain remarkably plastic, what prevents us from safely rebooting damaged memory circuits with targeted gene therapy today?
From Mice to Medicine: The 2026 Breakthrough in Reversing Adult Seizures and Cognitive Deficits via Meis2 Gene Therapy
Overview
In 2026, scientists at Mass General Brigham achieved a major breakthrough by using gene therapy to boost Meis2 in specific brain cells of adult mice. This restored the brain’s ability to adapt, corrected abnormal electrical activity, and led to a full recovery of memory and a dramatic drop in seizures. However, moving this therapy to humans faces big challenges: current viral delivery methods lack precision, and Meis2 can cause severe side effects if it acts outside the brain. High costs also risk making these treatments available only to the wealthy, raising concerns about fairness and social inequality.